Increased Afterload Augments Sunitinib-Induced Cardiotoxicity in an Engineered Cardiac Microtissue Model

Sunitinib, a multitargeted oral tyrosine kinase inhibitor, used widely to treat solid tumors, results in hypertension in up to 47% and left ventricular dysfunction in up to 19% of treated individuals. The relative contribution of afterload toward inducing cardiac dysfunction with sunitinib treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Truitt, Rachel, Mu, Anbin, Corbin, Elise A., Vite, Alexia, Brandimarto, Jeffrey, Ky, Bonnie, Margulies, Kenneth B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
PRECLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059907/
https://www.ncbi.nlm.nih.gov/pubmed/30062212
http://dx.doi.org/10.1016/j.jacbts.2017.12.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059907/
https://www.ncbi.nlm.nih.gov/pubmed/30062212
http://dx.doi.org/10.1016/j.jacbts.2017.12.007

Ejemplares similares